EC approves Brineura for CLN2

The European Commission approved Brineura cerliponase alfa (BMN 190) from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease...